Oruka Therapeutics, Inc.
Clinical trials sponsored by Oruka Therapeutics, Inc., explained in plain language.
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either the drug or a placebo to see if it can clear skin lesions. The main goal is to measure complete skin clearance at 16 weeks.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
New drug ORKA-002 tested in humans for first time
Knowledge-focused OngoingThis early-stage study tests the safety of a new drug called ORKA-002 in 24 healthy adults aged 18 to 65. Participants receive a single dose and are monitored for side effects and how the drug moves through the body. The goal is to gather initial safety data, not to treat any dis…
Phase: PHASE1 • Sponsor: Oruka Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 12:11 UTC